Inflation indexed bonds. Inflation will run hot for at least another 12-18 months. Fees are incredibly low, high liquidity. Benefits from inflation increases. Can't know what's going to happen long term, but you will benefit in the short term from this type of investment. Yield is 1.6%.

A recovery story. Best in class, best assets. Theme of stay at home will wane. There's a more hybrid solution, and its stable of smaller tech and healthcare tenants will benefit. Trades at a 15% discount to NAV. Yield is 4.04%. (Analysts’ price target is $45.23)

Digital and e-commerce transition. Cheap relative to its space and on an absolute basis. Having Shoppers as an asset is so powerful. Yield is 1.9%. (Analysts’ price target is $75.33)

Second largest global payments system after Visa. Taps into a more normal economic backdrop and especially lucrative travel transactions. Long growth runway of moving from cash to digital. Annualized revenue growth should grow to 17%. Yield is 0.47%. (Analysts’ price target is $392.65)

Based in Switzerland. World's largest wealth and asset manager. Universal Bank in Switzerland, and a global and investment bank. Solid balance sheet. Strong capital and liquidity metrics. Broad economic recovery will help European banks. Trading at just below book value. Shares look healthy technically speaking. Yield is 1.15%. (Analysts’ price target is $17.13)

Second largest in US by market cap, most international-focused by operating revenue. As pace of vaccine rollout accelerates, strong pent-up demand will cause airline traffic to surge. No dividend. (Analysts’ price target is $54.20)

Stockchase Research Editor: Michael O'Reilly Recently reported revenues were up 24%, including a 94% increase in direct to consumer sales. LULU holds $1.2 billion in cash and the stock is still trading 20% below its all-time highs. Clearly the pandemic has not hurt this Vancouver based stretchy pant manufacturer. We would buy this with a stop loss at $250, looking to achieve $385 -- upside potential over 26%. Yield 0% (Analysts’ price target is $385.35)

Stockchase Research Editor: Michael O'Reilly MP is a miner of rare earth metals and is the largest US producer of oxides used in magnets. These are used in consumer electronics, electric vehicles, robotics, wind turbines and more. It is a goal of the Biden Administration to ensure the US does not become dependent on China (who supplies 80% of US demand). Recently released EPS of $0.18 beat expectations of $0.04. Revenues were up 100% on the year as production increased 40%. We would buy this with a stop loss at $20, looking to achieve $46 -- upside potential of 33%. Yield 0% (Analysts’ price target is $45.60)

Stockchase Research Editor: Michael O'Reilly AZN is the COVID-19 vaccine producer that has been granted emergency use authorization in over 50 countries. It also has one of the best pipelines for new biotech drugs. They just acquired a strategic company that will further "boost" their immunology presence. The company pays a good dividend that is projected to have a payout ratio under 75% of cash flow next year. The company is estimated to have added over $2.3 billion to its cash reserves, which are now over $7.5 billion. We would buy this with a stop loss at $42, looking to achieve $64 -- upside potential of 28%. Yield 2.83% (Analysts’ price target is $63.73)

The yield curve is steepening which will help revenues. They have held reserves very well, and these are coming off and going to the bottom line now. The Fed after June will allow banks for buyback shares and increase their dividends, too. Also, BAC has lowered their costs and using technology more efficiently. The U.S. banks are seeing growth. Wealth management business is also increasing. It pays a reasonable dividend that's rising and it trades at only 13x PE. (Analysts’ price target is $38.63)

It trades at 17x PE. Cybersecurity will be an big issue as companies around the world (the recent MSFT breach is an example). We've digitized so quickly during Covid, so that's led to more security problems, and this won't go away. Federal governments around the world are looking into these bad actors. CHKP has many new products coming to serve the cloud business. They beat their quarter, but offered poor guidance, because they're moving to a subscription-based operation. That said, he expects growth in several more quarters. (Analysts’ price target is $133.10)

They produce medical devices for hips, knees, hands and ankles. Elective surgeries are coming back after pandemic lockdowns. SYK's medical products reduce medical stays and drug use, which benefits American hospitals and patients. Again demographics are another tailwind. He expects good growth. SYK holds a lot of fresh cash to pay debt and the dividend. (Analysts’ price target is $251.00)

This is a secular growth stock. They have been expanding rapidly in Asia. They are working on their e-commerce channels as it gives them a margin uplift vs. selling coats through third party retailers. They are also increasing their in-sourcing manufacturing so as to have better control over product quality. They are making key hires in the marketing and branding groups. It has pulled back after blockbuster numbers came out. (Analysts’ price target is $61.67)

Emerging markets are more volatile than developed markets. This is the most globally ambitious of the Canadian banks. The return on equity is lower than their peers and should be boosted this year. Their credit provisions last years were quite large compared to others but should face easy comparisons this year. He thinks the regulators will free them up later this year to increase dividends and possibly buy back shares. (Analysts’ price target is $80.41)